GAVRETO Now approved

GAVRETO™ is a once-daily oral targeted therapy for people living with RET-positive metastatic non-small cell lung cancer (NSCLC) or advanced thyroid cancer.

RET+=rearranged during transfection positive.

Check back in the coming days for more information on GAVRETO for the treatment of RET+ advanced thyroid cancer

Ask your doctor if GAVRETO
could be right for you.
Register for updates
about GAVRETO

RET+=rearranged during transfection positive.